Please provide your email address to receive an email when new articles are posted on . Tobramycin inhalation solution was effective in lowering bacterial density and positively influenced quality of ...

COLUMBIA, S.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of ...

The antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF. Tobramycin is an aminoglycoside antibiotic indicated for the treatment of serious bacterial ...

September 5, 2011 — In a 13-to-1 vote, a US Food and Drug Administration (FDA) advisory panel today said that evidence supports the safety and efficacy of tobramycin inhalation powder (TIP; TOBI ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...

The US Food and Drug Administration (FDA) approved a tobramycin inhalation powder (TOBI Podhaler, Novartis) for treating patients with cystic fibrosis (CF) whose lungs are infected with the bacterium ...

(RTTNews) - Integrated pharmaceutical company Dr. Reddy's Laboratories Ltd. (RDY) announced Tuesday the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI ...

Teva announced the launch of Tobramycin Inhalation Solution, the generic version of Novartis‘ Tobi. Tobi is approved for the management of cystic fibrosis in patients with Pseudomonas aeruginosa.

"Cystic fibrosis patients have many challenges to navigate and we are pleased to be able to offer BETHKIS as a management option for this chronic and debilitating condition," said Craig A. Collard, ...

EMERYVILLE, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)--Oct. 5, 2005--Chiron Corporation (Nasdaq:CHIR) and Nektar Therapeutics (Nasdaq:NKTR) today announced the initiation of clinical testing in the ...